Travere Therapeutics

Yahoo Finance • 5 days ago

Travere Therapeutics, Inc. (TVTX): A Bull Case Theory

We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.'s share was trading at $30.07 a... Full story

Yahoo Finance • 5 days ago

Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, highlighting significant growth for its flagship m... Full story

Yahoo Finance • 9 days ago

Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins

Earnings Call Insights: Travere Therapeutics (TVTX) Q4 2025 MANAGEMENT VIEW * CEO Eric Dube stated that "2025 was an incredible year for Travere, one that was defined by achieving a new high in the number of patients we were able to re... Full story

Yahoo Finance • 12 days ago

Is Travere Therapeutics (TVTX) Still Attractive After Recent Share Price Volatility?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. If you are wondering whether Travere Therapeutics at around US$27.82 still offers value, you are not alone, many investors... Full story

Yahoo Finance • 2 months ago

Dow Jones Futures Fall After Christmas; Nvidia Makes Big Deal

The Dow Jones set a record close and the S&P 500 hit an intraday high heading into the Christmas holiday. Palantir, Tesla, Google and Nvidia are in buy areas. Continue Reading... Full story

Yahoo Finance • 2 months ago

Dow Jones Futures Open After Market Holiday; S&P 500 At Highs

The Dow Jones set a record close and the S&P 500 hit an intraday high heading into the Christmas holiday. Palantir, Tesla, Google and Nvidia are in buy areas. Continue Reading... Full story

Yahoo Finance • 2 months ago

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday

Key Points One analyst believes the company's Filspari has blockbuster potential if it earns FDA approval for a new indication. A decision on that should come very shortly.10 stocks we like better than Travere Therapeutics › The stock of... Full story

Yahoo Finance • 3 months ago

Why IBD 50's No. 2 Stock, Travere Therapeutics, Has Doubled In 2025

Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, Filspari. Continue Reading View Comments... Full story

Yahoo Finance • 3 months ago

Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025

Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, Filspari. Continue Reading View Comments... Full story

Yahoo Finance • 3 months ago

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Key Points New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valu... Full story

Yahoo Finance • 4 months ago

Travere signals readiness for rapid FILSPARI launch in FSGS as Q3 2025 revenue hits $164.9M

Earnings Call Insights: Travere Therapeutics (TVTX) Q3 2025 MANAGEMENT VIEW * President and CEO Eric Dube emphasized "exceptional progress across our three key priorities: delivering strong commercial execution in IgA nephropathy, prep... Full story

Yahoo Finance • 4 months ago

Mid-America Apartment Communities' Series A Preferred Shares Crosses Above 7.5% Yield Territory

In trading on Tuesday, shares of Mid-America Apartment Communities Inc's 8 1/2% Series A Cumulative Redeemable Preferred Shares (Symbol: MAA.PRI) were yielding above the 7.5% mark based on its quarterly dividend (annualized to $4.25), with... Full story

Yahoo Finance • 5 months ago

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, October 10, 2025--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate o... Full story

Yahoo Finance • 5 months ago

Target initiated, Nike upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: RBC Capital upgraded Nike (NKE) to Out... Full story

Yahoo Finance • 5 months ago

Implied FYX Analyst Target Price: $122

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 6 months ago

Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside

We recently published AI Frenzy: 10 Stocks Crushing the Market, 6 Climb to Fresh Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the top performers on Wednesday. Travere Therapeutics, Inc. (NASDAQ:TVTX) soared to a new all-time... Full story

Yahoo Finance • 6 months ago

Notable Wednesday Option Activity: MCD, DAKT, TVTX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in McDonald's Corp (Symbol: MCD), where a total of 16,370 contracts have traded so far, representing approximately 1.6 million underl... Full story

Yahoo Finance • 7 months ago

Notable Wednesday Option Activity: TVTX, EL, SMR

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Travere Therapeutics Inc (Symbol: TVTX), where a total volume of 8,102 contracts has been traded thus far today, a contra... Full story

Yahoo Finance • 7 months ago

Travere Therapeutics price target raised to $32 from $30 at Wedbush

Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the shares. The firm notes Q2 update represented another strong showing for Filspari with Travere reporting a Filspari... Full story

Yahoo Finance • 7 months ago

Travere Therapeutics Inc (NASDAQ:TVTX) Surpasses Q2 2025 Expectations with Strong Revenue Growth and Narrower Loss

Travere Therapeutics Inc (NASDAQ:TVTX [https://www.chartmill.com/stock/quote/TVTX]) reported second-quarter 2025 financial results that exceeded analyst expectations, prompting a positive market reaction. The company posted revenue of $114... Full story